{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:12:00Z","timestamp":1792620720375,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","award":["25ek0109701"],"award-info":[{"award-number":["25ek0109701"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multigene panel testing has become an important component of hereditary cancer evaluation in Western practice. This shift has been driven by advances in next-generation sequencing, declining costs, and the increasing relevance of germline findings to treatment, surveillance, prevention, and cascade testing. In Japan, publication of The Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes with Multigene Panel Testing, 2025 Edition provided a timely framework for reconsidering how Western experience should inform domestic implementation. Evidence from the United States and Europe has fostered the view that multigene panel testing has replaced sequential single-gene testing as a first-line approach because of its broader diagnostic yield and growing use in routine care. However, broader detection does not automatically translate into broader clinical benefit. Multigene panel testing is most valuable when the pathogenic variants detected are sufficiently prevalent, highly penetrant, and linked to established surveillance, risk-reducing surgery, targeted therapy, or cascade testing. Broader panels may also increase variants of uncertain significance, psychological burden, and unnecessary management. This review examines why multigene panel testing came to be seen as a first-line approach, distinguishes diagnostic yield from meaningful clinical utility, and considers why Western adoption should inform Japanese practice not as a mandate for indiscriminate expansion, but as support for phased, quality-assured, utility-oriented integration.<\/jats:p>","DOI":"10.1093\/jjco\/hyag095","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:43:15Z","timestamp":1779882195000},"page":"1159-1166","source":"Crossref","is-referenced-by-count":1,"title":["Hereditary cancer multigene panel testing in the United States and Europe: real-world constraints and implications for responsible integration in Japan"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4150-7938","authenticated-orcid":false,"given":"Issei","family":"Imoto","sequence":"first","affiliation":[{"name":"Aichi Cancer Center Research Institute , 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681 ,","place":["Japan"]},{"name":"Risk Assessment Unit, Aichi Cancer Center Hospital , 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobue","family":"Takaiso","sequence":"additional","affiliation":[{"name":"Risk Assessment Unit, Aichi Cancer Center Hospital , 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-9158","authenticated-orcid":false,"given":"Akiyo","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Risk Assessment Unit, Aichi Cancer Center Hospital , 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681 ,","place":["Japan"]},{"name":"Department of Breast Oncology, Aichi Cancer Center Hospital , 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Makita","sequence":"additional","affiliation":[{"name":"Department of Genetic Counseling, Asahikawa Medical University Hospital , 2-1-1-1 Midorigaokahigashi, Asahikawa, Hokkaido 078-8510 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026100809070675500_ref1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026100809070675500_ref2","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026100809070675500_ref3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1200\/JCO.18.01489","article-title":"Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion","volume":"37","author":"Stoffel","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026100809070675500_ref4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1200\/JCO-24-02608","article-title":"Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline","volume":"43","author":"Yu","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100809070675500_ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-026-02078-x","article-title":"Sequencing approaches in hereditary cancer testing: strengths, limitations and future directions","author":"Belhadj","year":"2026","journal-title":"Eur J Hum Genet"},{"key":"2026100809070675500_ref6","volume-title":"The Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes with Multigene Panel Testing (MGPT)","year":"2025","edition":"2025"},{"key":"2026100809070675500_ref7","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamaoncol.2018.0644","article-title":"Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer","volume":"4","author":"Kurian","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026100809070675500_ref8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","article-title":"Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment","volume":"1","author":"Desmond","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026100809070675500_ref9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jmoldx.2015.04.009","article-title":"A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1,000 patients","volume":"17","author":"Lincoln","year":"2015","journal-title":"J Mol Diagn"},{"key":"2026100809070675500_ref10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026100809070675500_ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jlb\/lsad020","article-title":"Payer reimbursement practices and incentives for improving interpretation of germline genetic testing","volume":"10","author":"Deverka","year":"2023","journal-title":"J Law Biosci"},{"key":"2026100809070675500_ref12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40258-025-00949-w","article-title":"The cost effectiveness of genomic medicine in cancer control: a systematic literature review","volume":"23","author":"Bourke","year":"2025","journal-title":"Appl Health Econ Health Policy"},{"key":"2026100809070675500_ref13","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.annonc.2025.04.012","article-title":"Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO precision oncology working group recommendations","volume":"36","author":"Turnbull","year":"2025","journal-title":"Ann Oncol"},{"key":"2026100809070675500_ref14","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1200\/JCO.24.00662","article-title":"Selection of germline genetic testing panels in patients with cancer: ASCO guideline","volume":"42","author":"Tung","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026100809070675500_ref15","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026100809070675500_ref16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41436-020-00957-2","article-title":"Clinical and psychological outcomes of receiving a variant of uncertain significance from multigene panel testing or genomic sequencing: a systematic review and meta-analysis","volume":"23","author":"Mighton","year":"2021","journal-title":"Genet Med"},{"key":"2026100809070675500_ref17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13053-022-00229-x","article-title":"Psychological and health behaviour outcomes following multi-gene panel testing for hereditary breast and ovarian cancer risk: a mini-review of the literature","volume":"20","author":"Carlsson","year":"2022","journal-title":"Hered Cancer Clin Pract"},{"key":"2026100809070675500_ref18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13696998.2022.2152233","article-title":"A review of the cost-effectiveness of genetic testing for germline variants in familial cancer","volume":"26","author":"Teppala","year":"2023","journal-title":"J Med Econ"},{"key":"2026100809070675500_ref19","doi-asserted-by":"publisher","first-page":"e2355324","DOI":"10.1001\/jamanetworkopen.2023.55324","article-title":"Cost-effectiveness of gene-specific prevention strategies for ovarian and breast cancer","volume":"7","author":"Wei","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026100809070675500_ref20","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41436-021-01262-2","article-title":"Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer","volume":"23","author":"Hamilton","year":"2021","journal-title":"Genet Med"},{"key":"2026100809070675500_ref21","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41431-026-02015-y","article-title":"Priority European strategies for sustainable access to high-quality genetic counselling in cancer: a Delphi study","volume":"34","author":"McCrary","year":"2026","journal-title":"Eur J Hum Genet"},{"key":"2026100809070675500_ref22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s44276-024-00099-x","article-title":"Commentary: why is genetic testing underutilized worldwide? The case for hereditary breast cancer","volume":"2","author":"Pederson","year":"2024","journal-title":"BJC Rep"},{"key":"2026100809070675500_ref23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2023.9526","article-title":"Germline genetic testing after cancer diagnosis","volume":"330","author":"Kurian","year":"2023","journal-title":"JAMA"},{"key":"2026100809070675500_ref24","doi-asserted-by":"publisher","first-page":"e2400814","DOI":"10.1200\/PO-24-00814","article-title":"Real-world germline BRCA testing, poly(ADP-ribose) polymerase inhibitor utilization, and survival outcomes in HER2-negative metastatic breast cancer","volume":"9","author":"Yadav","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"2026100809070675500_ref25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.6004\/jnccn.2017.0022","article-title":"Payer coverage for hereditary cancer panels: barriers, opportunities, and implications for the precision medicine initiative","volume":"15","author":"Trosman","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"2026100809070675500_ref26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nbt.3912","article-title":"Payer coverage policies for multigene tests","volume":"35","author":"Phillips","year":"2017","journal-title":"Nat Biotechnol"},{"key":"2026100809070675500_ref27","doi-asserted-by":"publisher","first-page":"101329","DOI":"10.1016\/j.gim.2024.101329","article-title":"Payer perspectives on genomic testing in the United States: a systematic literature review","volume":"27","author":"Wiedower","year":"2025","journal-title":"Genet Med"},{"key":"2026100809070675500_ref28","author":"Centers for Medicare & Medicaid Services"},{"key":"2026100809070675500_ref29","volume-title":"National Genomic Test Directory","author":"NHS England"},{"key":"2026100809070675500_ref30","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3390\/jpm12081263","article-title":"Association between health insurance type and genetic testing and\/or Counseling for breast and ovarian cancer","volume":"12","author":"Mansur","year":"2022","journal-title":"J Pers Med"},{"key":"2026100809070675500_ref31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11606-020-06064-x","article-title":"Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center","volume":"36","author":"Chapman-Davis","year":"2021","journal-title":"J Gen Intern Med"},{"key":"2026100809070675500_ref32","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/jgc4.1257","article-title":"Ancestry-specific hereditary cancer panel yields: moving toward more personalized risk assessment","volume":"29","author":"Roberts","year":"2020","journal-title":"J Genet Couns"},{"key":"2026100809070675500_ref33","author":"The Japanese Association of Medical Sciences","year":"2022"},{"key":"2026100809070675500_ref34","first-page":"124","article-title":"Are you ready for MGPT? - publication of the Japanese Society for Hereditary Tumors Guidance: hereditary cancer syndrome with multigene panel testing, 2025 version and a report on a domestic survey","volume":"25","author":"Yoshida","year":"2026","journal-title":"J Hered Tumors"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/10\/1159\/68570367\/hyag095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/10\/1159\/68570367\/hyag095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:07:16Z","timestamp":1791464836000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/10\/1159\/8713071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,6,22]]},"published-print":{"date-parts":[[2026,10,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag095","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,6,22]]}}}